AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Cherry AG

Investor Presentation Mar 16, 2022

730_ip_2022-03-16_5ea18f75-1d65-4a15-8ccd-8b8ca91ba177.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

BERENBERG EU OPPORTUNITIES

Investor Presentation – March 16, 2022

BUSINESS AREA GAMING

THE CHERRY MX HISTORY

Innovation & Quality "Made In Germany"

THE CHERRY MX HISTORY

Innovation & Quality "Made In Germany"

EU Opportunities - March 16, 2022 11

EU Opportunities - March 16, 2022 12

ROG Strix Scope RGB Mechanical

Keyboard, ROG/Asus

"CHERRY INSIDE"

OMEN/HP

Distinguishes customer products

to achieve premium pricing

THE AWARD-WINNING SERIES – AESTHETICS MEETS GERMAN ENGINEERING CHERRY MX 2.0S, HC 2.2 and MC 2.1.

BUSINESS AREA PROFESSIONAL

  • State-of-the-art card terminal solution for workplaces in German healthcare telematics infrastructure

  • Approved by gematik GmbH and introduced for all service providers in the German healthcare system
  • iF Design Award 2021 in the category of medical devices

  • Clinics/hospitals

  • pharmacies
  • dentist and doctor offices
  • Continuously new customer groups added

  • High-resolution color display enables optimal readability and intuitive operation

  • Easily disinfectable touchscreen glass surface for hygiene
  • Optional patient PIN-Pad (PP-1516) can be easily connected via USB (launch 2022)
  • Can be operated without a power supply via Power-Over-Ethernet
  • Prepared for reading contactless cards by NFC interface

EU Opportunities - March 16, 2022 18

$IN \in M$
AS INDICATED
FY 2020* 9M 2021 FORECAST FY 2021
Revenue 130.2 123.4 around 170
EBITDA margin
[adj.]
28.5% 29.6% around 30%
$IN \in M$
AS INDICATED
ANALYST CONSENSUS
Revenue 168.8
EBITDA margin 26.7%
Components $+ + +$
Gaming Devices $+ +$
Peripherals $++$
Digital Health
  • Underlying multiple growth drivers and mega trends support mid- and long-term growth
  • Supply chain disruptions, particularly in China, and temporary fluctuations in the ordering behavior of customers expected to continue in H1/2022
  • Investments in organic growth will be reflected by somewhat subdued profitability margins in FY 2022
  • No direct exposure to Russia or Ukraine

STRATEGIC ELEMENTS FOR ORGANIC GROWTH

  • Expand global innovation leader position
  • Develop products at the edge of technology
  • Expand leading premium brand presence
  • Deepen global market penetration

INORGANIC GROWTH STRATEGY / M&A

  • Focus on 4 existing business units
  • Complementary products and markets
  • Increase geographical strength
  • Synergies for market access / sales channels

OPERATIONAL MEASURES FOR ORGANIC GROWTH

  • Increase number, knowledge and expertise of employees
  • Advanced innovation & development activities
  • Expand marketing activities in B-2-B and B-2-C markets
  • Increase capacity and degree of automation in production

M&A TARGET PROFILE

  • Geographic: USA, Europe, Asia
  • Revenue: EUR 15m EUR 35m
  • EBITDA / EBIT margins: double digit (%)
  • Product areas: complementary products e. g. headsets, mice, video collaboration, microphones, other peripherals, ergonomic devices, etc.
Date Detail
March 31 Publication Annual Financial Report
April $4-5$ US Roadshow (virtual)
April 7 MicroCap Days 2022
May 11 Publication Quarterly Financial Report (call-date Q1)
May $12 - 13$ Stockpicker Summit
May $23 - 25$ Equity Forum
June 8 Annual General Meeting
August 11 Publication Half-yearly Financial Report
September $5 - 6$ Equity Forum
November 15 Publication Quarterly Financial Report (call-date Q3)
November 16 Münchner Kapitalmarkt Konferenz
November 28 - 30 Eigenkapitalforum

Talk to a Data Expert

Have a question? We'll get back to you promptly.